Tyrone Lee, MD
Pulmonary Disease · Conway, ARNPI 1235108697
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,177 of the $3,684 with a category attached, or 86.2%. 26 manufacturers reported payments, led by AstraZeneca at 26.0% of the total. That places this record below the midpoint for pulmonary disease clinicians in AR, where the typical reported total is $3,332.
Across 197 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$958
- Mallinckrodt Hospital Products Inc.$577
- Electromed, Inc.$420
- Regeneron Healthcare Solutions, Inc.$312
- Sanofi$290
- Boehringer Ingelheim$288
- plus $841 from 20 others
What the payments were for
- Food & beverage$3,17786%
- Education$50814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $958 |
| Mallinckrodt Hospital Products Inc. | 29 | $577 |
| Electromed, Inc. | 20 | $420 |
| Regeneron Healthcare Solutions, Inc. | 13 | $312 |
| Sanofi | 18 | $290 |
| Boehringer Ingelheim | 18 | $288 |
| Philips North America LLC | 7 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $93 |
| United Therapeutics Corporation | 5 | $77 |
| Mylan Specialty L.p. | 4 | $66 |
| Pfizer | 4 | $60 |
| Actelion Pharmaceuticals US, Inc. | 4 | $60 |
| Baxter Healthcare | 3 | $46 |
| Hikma Pharmaceuticals USA | 3 | $42 |
| Harmony Biosciences LLC | 1 | $42 |
| Mallinckrodt Enterprises LLC | 3 | $40 |
| Johnson & Johnson | 3 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Vapotherm Inc | 1 | $27 |
| Circassia Inc. | 2 | $24 |
| CSL Behring | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Merck | 1 | $15 |
| Novartis | 1 | $15 |
| GSK | 1 | $12 |
How this compares
$3,684 in reported general payments places this provider in the 50th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 920 | $663,309 |
| OfevNintedanib Esylate | 28 | $351,559 |
| Breo ElliptaFluticasone/Vilanterol | 530 | $236,298 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 276 | $198,737 |
| Spiriva RespimatTiotropium Bromide | 284 | $183,113 |
| Incruse ElliptaUmeclidinium Bromide | 275 | $112,575 |
| SymbicortBudesonide/Formoterol Fumarate | 184 | $52,927 |
| Spiriva HandihalerTiotropium Bromide | 39 | $33,553 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,004 | $28,721 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 200 | $25,670 |
| DuleraMometasone/Formoterol | 56 | $22,633 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 95 | $19,116 |
| Wixela InhubFluticasone Propion/Salmeterol | 114 | $15,405 |
| Fluticasone Propionate | 1,275 | $14,993 |
| Advair DiskusFluticasone Propion/Salmeterol | 42 | $12,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $12 | $1,022,0151,766 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $288 | $534,672312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $958 | $251,663460 claims |
| MerckDulera | $15 | $22,63356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Conway
- Ladly AbrahamConway$371K
- Raga Deepak Reddy PalagiriConway$4K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
- Mark SiffordJonesboro$20K
- Zafirah SalmanNorth Little Rock$18K
- Dominika SzwedoNorth Little Rock$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.